Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review

• Published in: International journal of environmental research and public health Vol. 19; no. 5; p. 2833
• Main Authors: Haseeb, Abdul, Abourehab, Mohammed A. S., Almalki, Wesam Abdulghani, Almontashri, Abdulrahman Mohammed, Bajawi, Sultan Ahmed, Aljoaid, Anas Mohammed, Alsahabi, Bahni Mohammed, Algethamy, Manal, AlQarni, Abdullmoin, Iqbal, Muhammad Shahid, Mutlaq, Alaa, Alghamdi, Saleh, Elrggal, Mahmoud E., Saleem, Zikria, Radwan, Rozan Mohammad, Mahrous, Ahmad Jamal, Faidah, Hani Saleh
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28.02.2022; MDPI
• Subjects: Antibiotics; Antimicrobial agents; Bacterial infections; Bias; Clinical outcomes; Cohort Studies; HIV; Human immunodeficiency virus; Humans; Hyperkalemia; Kidney transplants; Mortality; Optimization; Pneumonia; Pneumonia, Pneumocystis - drug therapy; Pneumonia, Pneumocystis - epidemiology; Pneumonia, Pneumocystis - prevention & control; Retrospective Studies; Review; Rheumatoid arthritis; Systematic review; Trimethoprim, Sulfamethoxazole Drug Combination - adverse effects; Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use; dose optimization; co-trimoxazole; Pneumocystis jirovecii pneumonia; trimethoprim-sulfamethoxazole
• ISSN: 1660-4601; 1661-7827; 1660-4601
• DOI: 10.3390/ijerph19052833

(1) Background: Pneumocystis jirovecii pneumonia (PCP) has a substantial impact on the morbidity and mortality of patients, especially those with autoimmune disorders, thus requiring optimal dosing strategies of Trimethoprim–Sulfamethoxazole (TMP-SMX). Therefore, to ensure the safety of TMP-SMX, the...